Walbrook PR, which provides high quality Financial PR and Investor Relations to Small Cap and AIM listed companies, announces its appointment as Financial PR advisor to AIM listed healthcare company OptiBiotix Health plc (AIM: OPTI) following it move to AIM and IPO. Walbrook is ranked No.1 for Healthcare in the AIM Advisers Rankings Guide.
OptiBiotix was formed in March 2012 to develop compounds which modify the human microbiome – the collective genome of the microbes in the body – to prevent and manage human disease.�� The aim of OptiBiotix is to discover and develop microbial strains, compounds and formulations, which modulate the human microbiome and can be used as food ingredients and supplements or active compounds for the prevention and management of human metabolic diseases, examples of which include obesity, cholesterol and lipid distribution and diabetes.��
Paul McManus, Director of Walbrook PR, said:�"We are delighted to have been appointed by OptiBiotix Health plc as a client. The Company have a pipeline of natural compounds and formulations that have great potential in the fight against obesity, diabetes and high cholesterol. Walbrook has built up a very strong position in the Life Sciences space, which combines well with our passion for working growing businesses, securing our position as the No. 1 Financial PR agency for AIM listed healthcare stocks."